Should nephrologists use beta-blockers? A perspective

Nephrology Dialysis Transplantation

Volumn 24, Issue 3, 2009, Pages 701-702

  Kalaitzidis, Rigas ^a   Bakris, George ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Beta blockers; Dialysis; Hypertension; Kidney; Mortality

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; HYDROCHLOROTHIAZIDE; METOPROLOL; NEBIVOLOL; OXPRENOLOL;

CHRONIC KIDNEY DISEASE; DRUG EFFECT; GLOMERULOSCLEROSIS; HEART FAILURE; HEART INJURY; HEART RATE; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; NEPHROLOGIST; NONHUMAN; PRIORITY JOURNAL; RISK REDUCTION; SHORT SURVEY;

ADRENERGIC BETA-ANTAGONISTS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; HUMANS; HYPERTENSION; KIDNEY DISEASES;

EID: 60749084417     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn695     Document Type: Short Survey

References (23)

1. Abbott KC, Trespalacios FC, Agodoa LY et al. Beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 2004; 164: 2465-2471
2. Hart PD, Bakris GL. Should beta-blockers be used to control hypertension in people with chronic kidney disease? Semin Nephrol 2007; 27: 555-564
3. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int 2006; 70: 1905-1913
4. Salplachta J, Bartosikova L, Necas J. Effects of carvedilol and BL-443 on kidney of rats with cyclosporine nephropathy. Gen Physiol Biophys 2002; 21: 189-195
5. Converse RL Jr, Jacobsen TN, Toto RD et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-1918
6. Ligtenberg G, Blankestijn PJ, Oey PL et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-1328
7. Klein IH, Ligtenberg G, Oey PL et al. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12: 2427-2433
8. Hausberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974-1979
9. Sarafidis PA, Li S, Chen SC et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med 2008; 121: 332-340
10. Abbott KC, Trespalacios FC, Agodoa LY et al. Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 2004; 164: 2465-2471
11. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252
12. Turnbull F, Neal B, Ninomiya T et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121-1123
13. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002; 62: 1784-1790
14. Horl MP, Horl WH. Drug therapy for hypertension in hemodialysis patients. Semin Dial 2004; 17: 288-294
15. Cice G, Ferrara L, D'Andrea A et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41: 1438-1444
16. Weber MA, Bakris GL, Giles TD et al. Beta-blockers in the treatment of hypertension: new data, new directions. J Clin Hypertens (Greenwich) 2008; 10: 234-238
17. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553
18. Sarafidis P, Bogojevic Z, Basta E et al. Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich) 2008; 10: 112-118
19. Bangalore S, Wild D, Parkar S et al. Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol 2008; 52: 1062-1072
20. Kannel WB, Kannel C, Paffenbarger RS Jr et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1489-1494
21. Dyer AR, Persky V, Stamler J et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 1980; 112: 736-749
22. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225
23. Wright JT Jr, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431